Axsome Therapeutics, Inc. - 8-K Filing
Axsome Therapeutics announced a settlement resolving all patent litigation related to its product SUNOSI (solriamfetol). The company will grant five companies the right to sell generic versions of SUNOSI beginning on or after September 1, 2040 if pediatric exclusivity is granted, or March 1, 2040 otherwise. No other patent litigation related to SUNOSI remains pending. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $AXSM